Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Background Chronic kidney disease (CKD) has emerged as a possible new risk factor of cognitive impairment and dementia, but results of studies remain conflicting. Methods A systematic literature research of electronic databases (MEDLINE, Cochrane Library and Goggle Scholar covering the period from 1980 to January 2012) and meta-analysis of relevant cross-sectional and longitudinal studies were conducted to assess the association of CKD and cognitive decline. Results Most cross-sectional and longitudinal studies suggest an association between cognitive impairment and CKD. Meta-analysis of cross-sectional and longitudinal studies comprising 54,779 participants yielded an association of cognitive decline in patients with CKD compared with patients without CKD (OR 1.65, 95% CI 1.32-2.05; p Conclusion This is the first meta-analysis assessing the impact of CKD on cognitive decline. Our results suggest CKD being a significant and independent somatic risk factor in the development of cognitive decline.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Etgen, T., Chonchol, M., Förstl, H., & Sander, D. (2012). Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. American journal of nephrology. https://doi.org/10.1159/000338135

Vancouver

Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. American journal of nephrology. 2012. doi:10.1159/000338135. PMID: 22555151.

BibTeX

@article{etgen2012-22555151,
  author  = {Etgen, T. and Chonchol, M. and Förstl, H. and Sander, D.},
  title   = {{Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis}},
  journal = {American journal of nephrology},
  year    = {2012},
  doi     = {10.1159/000338135},
  pmid    = {22555151},
  url     = {https://doi.org/10.1159/000338135}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This meta-analysis of 54,779 participants found that people with chronic kidney disease had higher odds of cognitive decline than those without it. It suggests chronic kidney disease is a significant and independent risk factor for cognitive decline, but does not test any treatment or prevention.

Study details

Limitations

The abstract's own conclusion is described only in general terms (“most studies suggest an association”) without a pooled effect size, and it draws on a mix of cross-sectional and longitudinal designs, which differ in how well they can establish which came first.

How this study scored 69/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 69 of 100.69 of 100 points earned31 not earned

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (American journal of nephrology)
Journal's citation record 1 / 4 American Journal of Nephrology: journal h-index 127 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 4 / 4 54,779 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 A review of other studies — randomisation is not credited here
Times cited 6 / 7 Cited 362 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 22.6 citations a year over 16 year(s) since 2012
Impact for its field and year 2 / 6 Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 3 / 4 Cited 85 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Dirk Sander: h-index 51 (OpenAlex, whole career)
Institution's track record 1 / 3 Technical University of Munich: institution h-index 1,092 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22555151)
Free to read 0 / 2 Behind a paywall — scores zero
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Risk factors

Also tagged “examination”

840 studies in the library carry the topic tag “examination”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Similar studies

More on Risk factors

See all studies in Risk factors →